echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Inhibition of the RAS pathway can also affect protein degradation and the initial clinical results of innovative therapies for fatal brain cancer are positive

    Inhibition of the RAS pathway can also affect protein degradation and the initial clinical results of innovative therapies for fatal brain cancer are positive

    • Last Update: 2021-11-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 4, 2021, Chimerix announced that ONC201, an investigational therapy with a dual mechanism of action, has achieved positive top-line results in clinical trials for the treatment of recurrent gliomas


    ONC201 targets DRD2 and ClpP at the same time, blocking DRD2 can inhibit the RAS signaling pathway, and activating ClpP can promote the degradation of proteins in the mitochondria of cells that are related to the survival of cancer cells


    ▲The mechanism of ONC201 (picture source: reference [2])

    The 50 patients whose efficacy can be evaluated in this trial have diffuse midline gliomas, which carry the H3 K27M mutation.


    In terms of safety, the complete safety data collection and analysis of the cohort are in progress, and one serious adverse event was attributed to ONC201


    "For these patients who do not have effective systemic treatment options, these data are exciting


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.